Literature DB >> 15885601

Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic.

Ari Zimran1, Irena Liphshitz, Micha Barchana, Aya Abrahamov, Deborah Elstein.   

Abstract

BACKGROUND: It has been implied that the incidence of malignant disorders is increased in patients with non-neuronopathic (type I) Gaucher disease. The purpose of the study was to ascertain numbers of cancers in type I Gaucher disease since this is of considerable concern to patients and physicians.
METHODS: Records of 505 patients with type I Gaucher disease seen at a large referral clinic since 1990 were culled in December 2004 to ascertain diagnosis of a cancer identified during follow-up. Age-matched data from the Israeli National Cancer Registry (INCR) database were used for comparison.
FINDINGS: Patients diagnosed with cancer before 1990 were not included. Of the remaining 500 patients, 227 (45.4%) were male, mean age=38.7 years; and 273 (54.6%) were female, mean age=37.0 years (SD=21.0 years for both). Twenty patients (4.0%) had developed a cancer through December 31, 2003: 6 were male and 14 were female. The most common were three cases each of lymphoma and myelodysplastic syndrome and two cases of multiple myeloma. There was no statistically significant excess of cancer rate among patients relative to age-matched rates reported in national Jewish Israeli and Ashkenazi Jewish Israeli registry records.
CONCLUSIONS: There appears to be no excess risk for hematological or other cancers among patients with type I Gaucher disease relative to the overall Jewish population matched for age. This study confirms recent international studies of patients with Gaucher disease for no excess risk for all cancers but multiple myeloma where these latter studies implicate a significantly higher incidence.

Entities:  

Mesh:

Year:  2005        PMID: 15885601     DOI: 10.1016/j.bcmd.2005.03.004

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  31 in total

1.  Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Authors:  Sarah M Lo; Philip Stein; Sean Mullaly; Michael Bar; Dhanpat Jain; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

2.  Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S.

Authors:  Marc N Offman; Marcin Krol; Israel Silman; Joel L Sussman; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

3.  The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients.

Authors:  Tamar H Taddei; Katherine A Kacena; Mei Yang; Ruhua Yang; Advitya Malhotra; Michael Boxer; Kirk A Aleck; Gadi Rennert; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

4.  The risk of Parkinson's disease in type 1 Gaucher disease.

Authors:  Gilberto Bultron; Katherine Kacena; Daniel Pearson; Michael Boxer; Ruhua Yang; Swati Sathe; Gregory Pastores; Pramod K Mistry
Journal:  J Inherit Metab Dis       Date:  2010-02-23       Impact factor: 4.982

5.  Recent advances in the diagnosis and management of Gaucher disease.

Authors:  Sam E Gary; Emory Ryan; Alta M Steward; Ellen Sidransky
Journal:  Expert Rev Endocrinol Metab       Date:  2018-03-12

6.  A reappraisal of Gaucher disease-diagnosis and disease management algorithms.

Authors:  Pramod K Mistry; Maria Domenica Cappellini; Elena Lukina; Hayri Ozsan; Sara Mach Pascual; Hanna Rosenbaum; Maria Helena Solano; Zachary Spigelman; Jesús Villarrubia; Nora Patricia Watman; Gero Massenkeil
Journal:  Am J Hematol       Date:  2011-01       Impact factor: 10.047

7.  Gaucher disease: resetting the clinical and scientific agenda.

Authors:  Pramod K Mistry; Neal J Weinreb; Roscoe O Brady; Gregory A Grabowski
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

8.  Life expectancy in Gaucher disease type 1.

Authors:  Neal J Weinreb; Patrick Deegan; Katherine A Kacena; Pramod Mistry; Gregory M Pastores; Priscilla Velentgas; Stephan vom Dahl
Journal:  Am J Hematol       Date:  2008-12       Impact factor: 10.047

Review 9.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

10.  Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy.

Authors:  Shiny Nair; Noffar Bar; Mina L Xu; Madhav Dhodapkar; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-02-05       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.